Immune checkpoint PTPN2 predicts prognosis and immunotherapy response in human cancers
Background: PTPN2, a member of the non-receptor protein tyrosine phosphatases family, holds a crucial role in tumorigenesis and cancer immunotherapy. However, most studies on the role of PTPN2 in cancer are limited to specific cancer types. Therefore, this study aimed to investigate the prognostic s...
Main Authors: | Xiaolong Tang, Xue Sui, Yongshuo Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-01-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023000804 |
Similar Items
-
PTPN2 in the Immunity and Tumor Immunotherapy: A Concise Review
by: Jiachun Song, et al.
Published: (2022-09-01) -
PTPN1 is a prognostic biomarker related to cancer immunity and drug sensitivity: from pan-cancer analysis to validation in breast cancer
by: Ruijun Zhao, et al.
Published: (2023-10-01) -
Prognostic value and immunological role
of PTPN21 in pan-cancer analysis
by: Yane Yang, et al.
Published: (2023-07-01) -
Immune Pathways with Aging Characteristics Improve Immunotherapy Benefits and Drug Prediction in Human Cancer
by: Xinyue Wang, et al.
Published: (2023-01-01) -
Roles of HMGBs in Prognosis and Immunotherapy: A Pan-Cancer Analysis
by: Tong Lin, et al.
Published: (2021-10-01)